UK markets close in 7 hours 28 minutes

Altimmune, Inc. (0A4C.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
5.29+0.15 (+2.92%)
As of 04:24PM BST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.44
52-week change 3N/A
S&P500 52-week change 3-6.14%
52-week high 35.32
52-week low 35.08
50-day moving average 3N/A
200-day moving average 3N/A

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 5N/A
Implied shares outstanding 6N/A
Float 835.11M
% held by insiders 15.46%
% held by institutions 178.66%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2021
Most-recent quarter (mrq)31 Mar 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)-2,556.41%

Management effectiveness

Return on assets (ttm)-24.51%
Return on equity (ttm)-47.14%

Income statement

Revenue (ttm)3.6M
Revenue per share (ttm)0.09
Quarterly revenue growth (yoy)-96.20%
Gross profit (ttm)-69.43M
EBITDA -91.55M
Net income avi to common (ttm)-101.66M
Diluted EPS (ttm)-2.39
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)179.95M
Total cash per share (mrq)4.19
Total debt (mrq)1.44M
Total debt/equity (mrq)0.78
Current ratio (mrq)9.99
Book value per share (mrq)4.31

Cash flow statement

Operating cash flow (ttm)-72.19M
Levered free cash flow (ttm)-41.96M